Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biomea Fusion, Inc. BMEA
$33.83
+$1.82 (5.39%)
На 18:04, 12 мая 2023
-52.70%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1239847874.00000000
-
week52high
36.68
-
week52low
3.45
-
Revenue
0
-
P/E TTM
-10514
-
Beta
-1.03011800
-
EPS
-2.75000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 мая 2023 г. в 04:00
Описание компании
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 12 янв 2022 г. | |
| Oppenheimer | Outperform | 17 дек 2021 г. | |
| Piper Sandler | Overweight | 11 мая 2021 г. | |
| JP Morgan | Overweight | 11 мая 2021 г. | |
| Jefferies | Buy | 11 мая 2021 г. | |
| EF Hutton | Buy | 01 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 31 окт 2022 г. |
| EF Hutton | Buy | Buy | 08 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 13 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Butler Thomas Andrew | A | 354350 | 354350 | 06 янв 2023 г. |
| Valle Franco | A | 126300 | 126300 | 06 янв 2023 г. |
| Erdtmann Rainer M | A | 118000 | 118000 | 06 янв 2023 г. |
| Valle Franco | A | 19925 | 2518 | 30 ноя 2022 г. |
| Hitchcock Michael J.M. | A | 5000 | 5000 | 14 ноя 2022 г. |
| Valle Franco | A | 17407 | 4100 | 11 ноя 2022 г. |
| A2A Pharmaceuticals, Inc. | D | 4300000 | 30684 | 16 авг 2022 г. |
| A2A Pharmaceuticals, Inc. | D | 4330684 | 34658 | 21 июл 2022 г. |
| A2A Pharmaceuticals, Inc. | D | 4365342 | 34658 | 24 июн 2022 г. |
| Ray Sumita | A | 23867 | 23867 | 22 июн 2022 г. |
Новостная лента
Why Shares of Biomea Fusion Jumped This Week
The Motley Fool
20 янв 2023 г. в 11:30
The company launched its second trial this year for its lead therapy.
Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up
Zacks Investment Research
18 янв 2023 г. в 12:48
Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:19
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will present preclinical data of investigational covalent FLT3 inhibitor, BMF-500, at the 64th ASH Annual Meeting, which will be held from December 10-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Biomea Fusion to Present New Preclinical Data Showing BMF-219's Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
GlobeNewsWire
26 мая 2022 г. в 18:30
REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will present new data at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating BMF-219's activity in ex vivo preclinical models of CLL. In addition, the company will present a Trial In Progress (TIP) poster presentation detailing the design of COVALENT-101. Once released at the ASCO Annual Meeting, the preclinical and TIP presentations can be viewed on Biomea's website at https://biomeafusion.com/publications .
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference
GlobeNewsWire
20 мая 2022 г. в 13:30
REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Biomea will attend the H.C. Wainwright Global Investment Conference virtually and will participate in 1x1 meetings held by the conference organizers.